目前正在进行的多发性硬化症的第二阶段药物:我们是否可以打破第三阶段试验的局?
Silvia Susin-Calle1, Jose Enrique Martinez-Rodriguez1, Elvira Munteis1
1Department of Neurology, Hospital del Mar Research Institute and Pompeu Fabra University, Barcelona, Spain.
Expert opinion on investigational drugs
|February 25, 2025
概括
研究多发性硬化症 (MS) 的新疗法在第二阶段试验中显示出前景. 然而,将这些发现转化为渐进性多发性硬化症的第三阶段试验仍然存在挑战,需要更好的生物标志物和试验设计.
科学领域:
- 神经学 神经学
- 临床试验 临床试验
- 神经免疫学 神经免疫学
背景情况:
- 多发性硬化症 (MS) 是一种具有炎症和神经退行性成分的慢性中枢神经系统疾病.
- 目前的疾病修饰疗法对复发性多发性硬化症有效,但进展性多发性硬化症具有重大临床挑战.
- 对于针对MS的炎症和神经退行症的新型治疗策略有着至关重要的需求.
研究的目的:
- 审查最近和正在进行的多发性硬化症治疗的2期临床试验.
- 根据治疗目标对试验进行分类:免疫调节,神经保护和复髓化.
- 突出有前途的治疗方法,解决MS的双重病理.
主要方法:
- 在PubMed和ClinicalTrials.gov.gov的综合文献搜索.
- 对多发性硬化症的第二阶段临床试验的识别.
- 根据治疗方法对试验进行分类 (免疫调节,神经保护,复髓化).
主要成果:
- 第二阶段试验正在探索MS的各种治疗途径.
- 这些试验的新兴结果为潜在的未来治疗提供了洞察力.
- 显而易见的是,重点是针对MS的炎症和神经退行性方面治疗.
结论:
- 将第二阶段的成功转化为MS的第三阶段试验受到生物标志物的限制和试验设计问题的阻碍.
- 完善生物标志物,标准化结果定义 (例如,PIRA) 和改进试验设计对于推进多发性硬化治疗至关重要.
- 解决渐进性多发性硬化症的复杂性需要临床试验方法学的创新方法.
相关概念视频
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:26Drug Administration and Therapy Phases: Overview
402
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
402
01:26Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
176
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
176
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:22Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147